Dabigatran etexilate Recruiting Phase 4 Trials for Pulmonary Embolism (PE) / Dabigatran Etexilate / Angiographically Confirmed Acute Massive Pulmonary Embolism Treated With Endovascular Mechanical Fragmentation and Thrombolytic Therapy / Warfarin / Recurrence of DVT Treatment

IndicationsStatusPurposePhase
RecruitingTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT02596555Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for Acute Intermediate-Risk Pulmonary Embolism.
NCT02979561Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy